EXPLORING THE AVAILABILITY & CHARACTERISTICS OF HEALTH CARE COST DATA ACROSS SELECTED ASIAN COUNTRIES

Author(s)

Sandeep Duttagupta, PhD, Director of Outcomes Research1, Sutinder Bindra, MD, Medical Affairs2, Bonny SW Chan, B, Sc, MPhil student3, Chang Hongxia, MD, HCB4, Soo-Kiang Cheah, MD, Regulatory Affairs5, Yu Wei, MS, Sr. Product Physician4, Jingming Zhong, NA, Medical Affairs Manager4, Joyce Sze-Man Lai, MS, Med. Inf. Officer6, Sanjay Somasundaram, Dr, Medical Advisor7, Viraj Suvarna, Dr, Senior Medical Advisor7, Stephen Nawawi, Dr, Medical Manager8, Hyun-Jung Lee, Dr, Product Physician9, Hye-Jin Park, MS, Clinical Research Manager9, Ahmed Nawaz, Dr, Clinical Research Assoc10, Francisco Tranquilino, Dr, Prod. Phy. - Hypertension11, Naomi Martin, BS, Business Development Mgr11, Sharmila Ramachandran, Dr, Prod. Phy12, Susila Kulasingham, Dr, Prod. Phy13, Kian Ming Lam, Dr, Product Physician14, Maggie Li, Ms, Safety & Med. Info Mgr15, Stephen Lin, Dr, Prod. Phy15, Carik Chu, MS, CRA16, Kanokwan Ponprasit, Dr, Prod. Phy17, Wimol Nganthavee, Dr, Prod. Phy17, Arup Pramanik, Dr, Reg. Manager181Pfizer Inc, New York, NY, USA; 2 Pfizer Asia Regional Office, Hong Kong, Hong Kong; 3 The Chinese University of Hong Kong, Hong Kong, China; 4 Pfizer China, Beijing, China; 5 Pfizer Singapore, Singapore, Singapore; 6 Pfizer Hong Kong, North Point, Hong Kong; 7 Pfizer India, Jogeshwari, Mumbai, India; 8 Pfizer Indonesia, Jakarta, Indonesia; 9 Pfizer Korea, Seoul, South Korea; 10 Pfizer Pakistan, West Wharf, Karachi, Pakistan; 11 Pfizer Phillipines, Makati City, Philippines; 12 Pfizer, Selangor, Malaysia; 13 Pfizer Malaysia, Selangur Darul, Malaysia; 14 Pfizer Singapore, Gateway East, Singapore; 15 Pfizer Taiwan, Tamsui, Taiwan, China; 16 Pfizer Taiwan, Tamsui, China; 17 Pfizer Thailand, Bangkok, Thailand; 18 Pfizer Asia, Admiralty, Hong Kong

OBJECTIVE: Increasingly local and regional health care payers are requesting economic analyses for new drugs in order to effectively allocate resources in various Asia-Pacific countries. However, the availability of uniform and reliable local or regional data sources necessary to conduct such analyses is limited. In an effort to better understand the availability and characteristics of the health economic data sources from selected countries in this region, the following exercise was conducted. We collaborated with various institutions across selected Asian markets to gather relevant data to identify opportunities for economic analyses reflecting local and/or regional health care practices. METHODS: A list of commonly used health care services associated with hospitalized patients was developed from published literature. Health care institutions were approached to provide corresponding unit cost data, while keeping within respective country-specific privacy regulations. In addition, wherever available, costs from published sources were also collected. RESULTS: Indicative of the social, cultural and economic diversity of the region, health care service costs varied considerably across the selected countries. Cost for a comparable hospital bed/day in a private ward varied from as little as US$32 in Indonesia to US$72 in Pakistan. Significant differences were also seen in the cost per bed/day in a comparable ICU setting, ranging from as little US$271 in Singapore to US$1800 in Hong Kong Significant variances were also observed for cost data collected on a number of comparable inpatient and outpatient services. CONCLUSIONS: While progress is being made to develop pharmacoeconomic analyses specific to health care demand in the Asia-Pacific region, the quantity and quality of available data to meet these demands are still very limited.

Conference/Value in Health Info

2006-03, ISPOR Asia Pacific 2006, Shanghai, China

Code

PHP12

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Multiple Diseases

Explore Related HEOR by Topic

Economic Evaluation

Presentation